CDH1 c-160a promotor polymorphism is not associated with risk of stomach cancer.
We have combined data from case control studies designed to test the hypothesis that the c-160a promotor polymorphism in the gene coding for the cell adhesion molecule E-cadherin (CDH1) is associated with stomach cancer. A total of 899 individuals (433 patients and 466 controls) were analyzed. The genotype frequencies did not differ significantly between cases and controls, and the genotype-specific risks were not significantly different from unity, with an odds ratio for heterozygotes compared with the common homozygote of 1.3 (95% CI 0.98-1.8) and 1.2 (0.68-2.0) for rare homozygotes compared with common homozygotes. We found no evidence for differences in risk for the intestinal- and diffuse-type histopathologic subgroups.
Pharoah
Paul D P
PD
Department of Oncology, University of Cambridge, Strangeways Research Laboratories, Cambridge, United Kingdom.
Oliveira
Carla
C
Machado
José Carlos
JC
Keller
Gisella
G
Vogelsang
Holger
H
Laux
Holger
H
Becker
Karl-Friedrich
KF
Hahn
Heidi
H
Paproski
Suzanne M
SM
Brown
Lindsay A
LA
Caldas
Carlos
C
Huntsman
David
D
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015820:Cadherins / Q000235:genetics*; D002170:Canada; D005260:Female; D005787:Gene Frequency; D020022:Genetic Predisposition to Disease; D005858:Germany; D006801:Humans; D008297:Male; D008875:Middle Aged; D016017:Odds Ratio; D011110:Polymorphism, Genetic / Q000235:genetics*; D011174:Portugal; D011401:Promoter Regions, Genetic / Q000235:genetics*; D013274:Stomach Neoplasms / Q000209:etiology / Q000235:genetics*
D015820:Cadherins